Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Solid margins ⢠High leverage ⢠Weak cash flow PAHC offers solid profitability and reasonable valuation, but high leverage, inventory-heavy liquidity, and weak free-cash-flow coverage warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly gain ⢠Near-term pullback ⢠Overbought momentum Support Level: $37.55â$37.60 Resistance Level: $39.92â$40.00 PAHC gained ~12% over the last month and remains bullish above key moving averages, but with RSI near 69, watch $40.00 resistance and $37.55 support.
Sentiment & News
Key News Insights: ⢠Record sales ⢠Earnings beat ⢠Weak trading Phibro delivered record fiscal 2026 sales and an earnings beat, but shares remain technically weak despite integration and efficiency-driven growth prospects.
AI Summary
PAHC's investment case has shifted from earnings recovery to proving that acquisition-driven EBITDA can convert into free cash flow through inventory reduction and deleveraging; investors should favor confirmation of working-capital normalization and debt paydown over further adjusted-EPS beats.
Description
Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum. | Closed | -7.8% |
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile. | Closed | +12.8% |